Aileron Therapeutics (ALRN) Financials

$2.05

$-0.06 (-2.84%)

As on 07-Feb-2025 09:30EDT

Market cap

$46 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	0.13	--	--	--	--	--
Cost of Revenue	0.06	0.12	0.17	0.12	0.16	0.16
Gross Profit	-0.06	-0.12	-0.17	-0.12	-0.16	-0.16
Operating Expenses	29.62	16.28	27.65	26.61	20.50	29.96
Operating Profit (EBIT)	-29.62	-16.28	-27.65	-26.61	-20.50	-29.96
Other Income	--	--	--	--	-0.66	--
Profit before Tax	-29.19	-15.73	-27.33	-26.21	-21.16	-29.37
Provision for Tax	-0.06	0.93	-0.32	-0.44	0.66	-0.59
Profit after Tax (Net Income)	-29.24	-15.73	-27.01	-25.76	-21.82	-28.78
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	-27.33	-26.16	-21.16	-29.37

Liabilities ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	50.23	6.89	18.62	43.90	12.16	16.05
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	48.33	94.74	1.75	0.07	0.22	4.59
Current Liabilities	5.66	4.39	3.38	4.51	3.96	5.84
Total Liabilities	109.88	106.01	22.01	48.48	16.34	26.47

Assets ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	85.53	87.74	0.13	0.30	0.02	6.92
Current Assets	18.68	18.27	21.87	48.18	16.33	19.55
Total Assets	109.88	106.01	22.01	48.48	16.34	26.47
Total Debt*	--	0.05	0.03	0.16	0.39	5.03
Net Current Assets	13.03	13.88	18.49	43.67	12.37	13.71

Cashflow ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-19.81	-24.87	-23.75	-20.48	-26.47
Cash Flow from Investing Activities	--	--	26.46	-35.92	6.41	-2.81
Cash from Financing Activities	--	15.79	0.00	55.66	15.80	23.96
Net Cash Inflow / Outflow	--	--	--	--	1.74	-5.32

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	-122.95	-86.13	-91.01	-129.76	-125.08
ROE (%)	-41.31	-123.34	-86.40	-91.91	-154.68	-161.48
ROA (%)	-47.04	-24.58	-76.64	-79.49	-101.92	-101.37
EBIT Margin (%)	-12,122.39	--	--	--	--	--
Net Margin (%)	-21,821.64	--	--	--	3,300.76	--
Cash Profit Margin (%)	-0.19	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-17.21	43.10	-3.92	-29.81	31.58	6.10
Net Profit Growth (%)	-132.96	41.76	-4.84	-18.09	24.20	8.76
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	--	--	--	--	--	--
Price / Book Value	0.88	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.64	1.11	0.77	1.73	0.66	0.44
Close Price ($)	3.54	3.05	2.37	225.16	416.00	229.20
High Price ($)	7.42	5.49	300.00	932.00	988.00	1,040.00
Low Price ($)	1.01	1.01	1.79	204.00	100.00	160.00
Market Cap ($ Cr)	45.72	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	--	0.01	0.00	0.00	0.03	0.31
Short term debt to equity ratio	--	0.01	0.00	0.00	0.01	0.03
Current Ratio	3.30	4.17	6.46	10.69	4.12	3.35
Quick Ratio	3.30	--	--	--	--	--
Interest Coverage	-13.28	--	-86.94	-66.51	--	--

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	0.00	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	4,465.87	3,166.22	4,235.09	3,414.98	3,750.29
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.